Compositions and methods for coating medical implants

a technology of medical implants and compositions, applied in the direction of prosthesis, catheters, therapy, etc., can solve the problems of increasing morbidity for patients, over $2 billion annually, and major healthcare problems affecting the infection of medical implants

Inactive Publication Date: 2006-06-15
ANGIOTECH INT AG (CH)
View PDF99 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028] These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth herein which describe in more detail certain procedures or compositions (e.g., compounds o...

Problems solved by technology

Infections associated with medical implants represent a major healthcare problem.
Hospital acquired infections (nosocomial infections) are the 11th leading cause of death in the US and cost over $2 billion annually.
Once a medical implant becomes colonized by bacteria, it must frequently be replaced resulting in increased morbidity for the patient and increased cost to the healthcare system.
Often the infected device serves as a source for a disseminated infection which can lead to significant morbidity or even death.
One difficulty with these devices, however, is ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for coating medical implants
  • Compositions and methods for coating medical implants
  • Compositions and methods for coating medical implants

Examples

Experimental program
Comparison scheme
Effect test

example 1

MIC Determination by Microtitre Broth Dilution Method

[0335] A. MIC Assay of Various Gram Negative and Positive Bacteria

[0336] MIC assays were conducted essentially as described by Amsterdam, D. 1996. Susceptibility testing of antimicrobials in liquid media, p. 52-111. In Loman, V., ed. Antibiotics in laboratory medicine, 4th ed. Williams and Wilkins, Baltimore, Md. Briefly, a variety of compounds were tested for antibacterial activity against isolates of P. aeruginosa, K. pneumoniae, E. coli, S. epidermidus and S. aureus in the MIC (minimum inhibitory concentration assay under aerobic conditions using 96 well polystyrene microtitre plates (Falcon 1177), and Mueller Hinton broth at 37° C. incubated for 24 h. (MHB was used for most testing except C721 (S. pyogenes), which used Todd Hewitt broth, and Haemophilus influenzae, which used Haemophilus test medium (HTM)) Tests were conducted in triplicate. The results are provided below in Table 1.

TABLE 1Minimum Inhibitory Concentrations...

example 2

Catheter—DIP Coating—Non-Degradable Polymer

[0339] A coating solution is prepared by dissolving 20 g ChronoFlex Al 85A (CT Biomaterials) in 100 mL DMAC:THF (40:60) at 50° C. with stirring. Once dissolved, the polymer solution is cooled to room temperature. 20 mg mitoxantrone is added to 2 mL of the polyurethane solution. The solution is stirred until a homogenious mixture is obtained. Polyurethane 7 French tubing is dipped into the polymer / drug solution and then withdrawn. The coated tube is air dried (80° C.). The sample is then dried under vacuum to further reduce the residual solvent in the coating.

example 3

Catheter—Dip Coating—Degradable Polymer

[0340] A coating solution is prepared by dissolving 2 g PLG (50:50) in 10 mL dichloromethane:methanol (70:30). Once dissolved, 20 mg mitoxantrone is added to the polymer solution. Once the solution is a homogeneous solution, polyurethane 7 French tubing is dipped into the solution and then withdrawn. The coated tube is air dried. The sample is then dried under vacuum to further reduce the residual solvent in the coating.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 10 / 447,309, filed May 27, 2003, now pending, which application claims the benefit under 35 U.S.C.§ 119(e) of U.S. Provisional Application Ser. No. 60 / 383,419, filed May 24, 2002, which applications are incorporated herein by reference in their entirety.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates generally to pharmaceutical compositions, methods, and devices, and more specifically, to compositions and methods which reduce the likelihood of an infection associated with a medical implant. [0004] 2. Description of the Related Art [0005] Infections associated with medical implants represent a major healthcare problem. For example, 5% of patients admitted to an acute care facility develop a hospital acquired infection. Hospital acquired infections (nosocomial infections) are the 11th leading cause of death in the US and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7072A61K31/7048A61K31/704A61K31/4745A61K31/525A61F2/16A61N1/375A61F2/18A61F2/20A61F2/24A61L27/00A61L27/34A61L27/54A61L29/00A61L29/16A61L31/10A61L31/16
CPCA61L27/34A61L27/54A61L29/16A61L2300/404A61L2300/416A61L29/085A61P31/00A61P43/00
Inventor HUNTER, WILLIAM L.GRAVETT, DAVID M.TOLEIKIS, PHILIP M.LIGGINS, RICHARD T.LOSS, TROY A.E.
Owner ANGIOTECH INT AG (CH)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap